Screener
Vertex Pharmaceuticals VRTX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiCost.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
| Line item | As of March 31, 2026 / Amortized Cost | As of March 31, 2026 / Gross Unrealized Gains | As of March 31, 2026 / Gross Unrealized Losses | As of March 31, 2026 / Fair Value | As of December 31, 2025 / Amortized Cost | As of December 31, 2025 / Gross Unrealized Gains | As of December 31, 2025 / Gross Unrealized Losses | As of December 31, 2025 / Fair Value |
|---|---|---|---|---|---|---|---|---|
| Asset-backed securities | 1,293.2 | 2.6 | (2.2) | 1,293.6 | 1,351.1 | 6.0 | (0.1) | 1,357.0 |
| Certificates of deposit | 36.6 | — | — | 36.6 | 26.2 | — | — | 26.2 |
| Corporate debt securities | 4,167.5 | 10.9 | (7.9) | 4,170.5 | 3,669.3 | 25.0 | (0.4) | 3,693.9 |
| Commercial paper | 29.6 | — | — | 29.6 | 14.6 | — | — | 14.6 |
| Total marketable available-for-sale debt securities | 7,479.6 | 16.9 | (13.2) | 7,483.3 | 7,175.3 | 44.3 | (0.6) | 7,219.0 |
| Corporate equity securities | 25.0 | — | (4.6) | 20.4 | 25.0 | — | (8.4) | 16.6 |
| Total marketable securities | 7,504.6 | 16.9 | (17.8) | 7,503.7 | 7,200.3 | 44.3 | (9.0) | 7,235.6 |
| Total cash equivalents and marketable securities | $10,074.4 | $16.9 | $(17.8) | $10,073.5 | $9,979.4 | $44.3 | $(9.0) | $10,014.7 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vertex Pharmaceuticals's cumulative cost basis?
- Vertex Pharmaceuticals (VRTX) reported cumulative cost basis of $25M in Q1 2026.
- How has Vertex Pharmaceuticals's cumulative cost basis changed year-over-year?
- Vertex Pharmaceuticals's cumulative cost basis decreased by 58.3% year-over-year, from $60M to $25M.
- What is the long-term trend for Vertex Pharmaceuticals's cumulative cost basis?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's cumulative cost basis has grown at a -13.4% compound annual growth rate (CAGR), from $51.43M to $25M.
Ask your AI about Vertex Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude